Download Files:
IONIS-MAPTRx
$726 – $2,064
Products Details
Product Description
– IONIS-MAPTRx (BIIB080) is the first Tau-lowering antisense oligonucleotide (ASO). IONIS-MAPTRx has the potential for the research of Alzheimer Disease[1].
Web ID
– HY-132582
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture)
Shipping
– Blue Ice
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– N/A
References
– [1]Methods for reducing tau expression. WO2023004390A1|[2]DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481. |[3]Rationale for and Development of IONIS-MAPTRx, the First Tau-lowering Antisense Oligonucleotide, in Patients with Mild AD|[4]Laurence Mignon, et al. Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006). Neurology Apr 2018, 90 (15 Supplement) S2.006.
CAS Number
– 2857842-32-9
Molecular Weight
– 7182.00
Compound Purity
– 91.82
SMILES
– [IONIS-MAPTRx]
Clinical Information
– Phase 2
Research Area
– Neurological Disease
Solubility
– H2O : 100 mg/mL (ultrasonic)
Target
– Tau Protein
Pathway
– Neuronal Signaling
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
